Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 189

1.

A Somatostatin Receptor Subtype-3 (SST3) Peptide Agonist Shows Antitumor Effects in Experimental Models of Nonfunctioning Pituitary Tumors.

Vázquez-Borrego MC, Gupta V, Ibáñez-Costa A, Gahete MD, Venegas-Moreno E, Toledano-Delgado Á, Cano DA, Blanco-Acevedo C, Ortega-Salas R, Japón MA, Barrera-Martín A, Vasiljevic A, Hill J, Zhang S, Halem H, Solivera J, Raverot G, Gálvez MA, Soto-Moreno A, Paez-Pereda M, Culler MD, Castaño JP, Luque RM.

Clin Cancer Res. 2020 Feb 15;26(4):957-969. doi: 10.1158/1078-0432.CCR-19-2154. Epub 2019 Oct 17.

PMID:
31624102
2.

A New Generation Somatostatin-Dopamine Analogue Exerts Potent Antitumoral Actions on Pituitary Neuroendocrine Tumor Cells.

Vázquez-Borrego MC, L-López F, Gálvez-Moreno MA, Fuentes-Fayos AC, Venegas-Moreno E, Herrera-Martínez AD, Blanco-Acevedo C, Solivera J, Landsman T, Gahete MD, Soto-Moreno A, Culler MD, Castaño JP, Luque RM.

Neuroendocrinology. 2020;110(1-2):70-82. doi: 10.1159/000500812. Epub 2019 Jul 5.

3.

Critical phosphate salt concentrations leading to altered micellar casein structures and functional intermediates.

Saricay Y, Hettiarachchi CA, Culler MD, Harte FM.

J Dairy Sci. 2019 Aug;102(8):6820-6829. doi: 10.3168/jds.2018-15746. Epub 2019 Jun 6.

PMID:
31178183
4.

Effects of novel somatostatin-dopamine chimeric drugs in 2D and 3D cell culture models of neuroendocrine tumors.

Herrera-Martínez AD, van den Dungen R, Dogan-Oruc F, van Koetsveld PM, Culler MD, de Herder WW, Luque RM, Feelders RA, Hofland LJ.

Endocr Relat Cancer. 2019 Jun;26(6):585-599. doi: 10.1530/ERC-19-0086.

PMID:
30939452
5.

International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature.

Günther T, Tulipano G, Dournaud P, Bousquet C, Csaba Z, Kreienkamp HJ, Lupp A, Korbonits M, Castaño JP, Wester HJ, Culler M, Melmed S, Schulz S.

Pharmacol Rev. 2018 Oct;70(4):763-835. doi: 10.1124/pr.117.015388. Review.

6.

Somatostatin Analogue Treatment Primarily Induce miRNA Expression Changes and Up-Regulates Growth Inhibitory miR-7 and miR-148a in Neuroendocrine Cells.

Døssing KBV, Kjær C, Vikeså J, Binderup T, Knigge U, Culler MD, Kjær A, Federspiel B, Friis-Hansen L.

Genes (Basel). 2018 Jul 4;9(7). pii: E337. doi: 10.3390/genes9070337.

7.

In1-ghrelin splicing variant is associated with reduced disease-free survival of breast cancer patients and increases malignancy of breast cancer cells lines.

Rincón-Fernández D, Culler MD, Tsomaia N, Moreno-Bueno G, Luque RM, Gahete MD, Castaño JP.

Carcinogenesis. 2018 Mar 8;39(3):447-457. doi: 10.1093/carcin/bgx146.

PMID:
29272342
8.

The oncogenic role of the In1-ghrelin splicing variant in prostate cancer aggressiveness.

Hormaechea-Agulla D, Gahete MD, Jiménez-Vacas JM, Gómez-Gómez E, Ibáñez-Costa A, L-López F, Rivero-Cortés E, Sarmento-Cabral A, Valero-Rosa J, Carrasco-Valiente J, Sánchez-Sánchez R, Ortega-Salas R, Moreno MM, Tsomaia N, Swanson SM, Culler MD, Requena MJ, Castaño JP, Luque RM.

Mol Cancer. 2017 Aug 29;16(1):146. doi: 10.1186/s12943-017-0713-9.

9.

The oncogenic role of the spliced somatostatin receptor sst5TMD4 variant in prostate cancer.

Hormaechea-Agulla D, Jiménez-Vacas JM, Gómez-Gómez E, L-López F, Carrasco-Valiente J, Valero-Rosa J, Moreno MM, Sánchez-Sánchez R, Ortega-Salas R, Gracia-Navarro F, Culler MD, Ibáñez-Costa A, Gahete MD, Requena MJ, Castaño JP, Luque RM.

FASEB J. 2017 Nov;31(11):4682-4696. doi: 10.1096/fj.201601264RRR. Epub 2017 Jul 13.

PMID:
28705809
10.

The effect of emulsifying salts on the turbidity of a diluted milk system with varying pH and protein concentration.

Culler MD, Saricay Y, Harte FM.

J Dairy Sci. 2017 Jun;100(6):4241-4252. doi: 10.3168/jds.2017-12549. Epub 2017 Apr 21.

11.

BIM-23A760 influences key functional endpoints in pituitary adenomas and normal pituitaries: molecular mechanisms underlying the differential response in adenomas.

Ibáñez-Costa A, López-Sánchez LM, Gahete MD, Rivero-Cortés E, Vázquez-Borrego MC, Gálvez MA, de la Riva A, Venegas-Moreno E, Jiménez-Reina L, Moreno-Carazo A, Tinahones FJ, Maraver-Selfa S, Japón MA, García-Arnés JA, Soto-Moreno A, Webb SM, Kineman RD, Culler MD, Castaño JP, Luque RM.

Sci Rep. 2017 Feb 9;7:42002. doi: 10.1038/srep42002.

12.

The truncated somatostatin receptor sst5TMD4 stimulates the angiogenic process and is associated to lymphatic metastasis and disease-free survival in breast cancer patients.

Gahete MD, Rincón-Fernández D, Durán-Prado M, Hergueta-Redondo M, Ibáñez-Costa A, Rojo-Sebastián A, Gracia-Navarro F, Culler MD, Casanovas O, Moreno-Bueno G, Luque RM, Castaño JP.

Oncotarget. 2016 Sep 13;7(37):60110-60122. doi: 10.18632/oncotarget.11076.

13.

Research Resource: Real-Time Analysis of Somatostatin and Dopamine Receptor Signaling in Pituitary Cells Using a Fluorescence-Based Membrane Potential Assay.

Günther T, Culler M, Schulz S.

Mol Endocrinol. 2016 Apr;30(4):479-90. doi: 10.1210/me.2015-1241. Epub 2016 Mar 11.

14.

Presence of sst5TMD4, a truncated splice variant of the somatostatin receptor subtype 5, is associated to features of increased aggressiveness in pancreatic neuroendocrine tumors.

Sampedro-Núñez M, Luque RM, Ramos-Levi AM, Gahete MD, Serrano-Somavilla A, Villa-Osaba A, Adrados M, Ibáñez-Costa A, Martín-Pérez E, Culler MD, Marazuela M, Castaño JP.

Oncotarget. 2016 Feb 9;7(6):6593-608. doi: 10.18632/oncotarget.6565.

15.

In1-ghrelin, a splice variant of ghrelin gene, is associated with the evolution and aggressiveness of human neuroendocrine tumors: Evidence from clinical, cellular and molecular parameters.

Luque RM, Sampedro-Nuñez M, Gahete MD, Ramos-Levi A, Ibáñez-Costa A, Rivero-Cortés E, Serrano-Somavilla A, Adrados M, Culler MD, Castaño JP, Marazuela M.

Oncotarget. 2015 Aug 14;6(23):19619-33.

16.

In1-ghrelin splicing variant is overexpressed in pituitary adenomas and increases their aggressive features.

Ibáñez-Costa A, Gahete MD, Rivero-Cortés E, Rincón-Fernández D, Nelson R, Beltrán M, de la Riva A, Japón MA, Venegas-Moreno E, Gálvez MÁ, García-Arnés JA, Soto-Moreno A, Morgan J, Tsomaia N, Culler MD, Dieguez C, Castaño JP, Luque RM.

Sci Rep. 2015 Mar 4;5:8714. doi: 10.1038/srep08714.

17.

Truncated somatostatin receptor variant sst5TMD4 confers aggressive features (proliferation, invasion and reduced octreotide response) to somatotropinomas.

Luque RM, Ibáñez-Costa A, Neto LV, Taboada GF, Hormaechea-Agulla D, Kasuki L, Venegas-Moreno E, Moreno-Carazo A, Gálvez MÁ, Soto-Moreno A, Kineman RD, Culler MD, Gahete MD, Gadelha MR, Castaño JP.

Cancer Lett. 2015 Apr 10;359(2):299-306. doi: 10.1016/j.canlet.2015.01.037. Epub 2015 Jan 28.

18.

Preclinical gastrointestinal prokinetic efficacy and endocrine effects of the ghrelin mimetic RM-131.

Van der Ploeg L, Laken H, Sharma S, Datta R, Halem H, Dong J, Touvay C, Teillot M, Noonan P, Tartaglia L, Stoner L, Henderson B, Gottesdiener K, Culler M.

Life Sci. 2014 Jul 25;109(1):20-9. doi: 10.1016/j.lfs.2014.06.003. Epub 2014 Jun 12.

PMID:
24931905
19.

The truncated isoform of somatostatin receptor5 (sst5TMD4) is associated with poorly differentiated thyroid cancer.

Puig-Domingo M, Luque RM, Reverter JL, López-Sánchez LM, Gahete MD, Culler MD, Díaz-Soto G, Lomeña F, Squarcia M, Mate JL, Mora M, Fernández-Cruz L, Vidal O, Alastrué A, Balibrea J, Halperin I, Mauricio D, Castaño JP.

PLoS One. 2014 Jan 21;9(1):e85527. doi: 10.1371/journal.pone.0085527. eCollection 2014.

20.

Cortistatin attenuates inflammatory pain via spinal and peripheral actions.

Morell M, Camprubí-Robles M, Culler MD, de Lecea L, Delgado M.

Neurobiol Dis. 2014 Mar;63:141-54. doi: 10.1016/j.nbd.2013.11.022. Epub 2013 Dec 9.

PMID:
24333694
21.

Characterization and sub-cellular localization of SS1R, SS2R, and SS5R in human late-stage prostate cancer cells: effect of mono- and bi-specific somatostatin analogs on cell growth.

Ruscica M, Magni P, Steffani L, Gatto F, Albertelli M, Rametta R, Valenti L, Ameri P, Magnaghi V, Culler MD, Minuto F, Ferone D, Arvigo M.

Mol Cell Endocrinol. 2014 Feb 15;382(2):860-70. doi: 10.1016/j.mce.2013.10.027. Epub 2013 Nov 5.

PMID:
24211300
22.

Investigation of biochemical diversity in a soybean lineage representing 35 years of breeding.

Harrigan GG, Culler AH, Culler M, Breeze ML, Berman KH, Halls SC, Harrison JM.

J Agric Food Chem. 2013 Nov 13;61(45):10807-15. doi: 10.1021/jf4032102. Epub 2013 Nov 4.

PMID:
24188091
23.

The novel somatostatin receptor 2/dopamine type 2 receptor chimeric compound BIM-23A758 decreases the viability of human GOT1 midgut carcinoid cells.

Zitzmann K, Andersen S, Vlotides G, Spöttl G, Zhang S, Datta R, Culler M, Göke B, Auernhammer CJ.

Neuroendocrinology. 2013;98(2):128-36. doi: 10.1159/000353784. Epub 2013 Jul 31.

PMID:
23797089
24.

Cortistatin inhibits migration and proliferation of human vascular smooth muscle cells and decreases neointimal formation on carotid artery ligation.

Duran-Prado M, Morell M, Delgado-Maroto V, Castaño JP, Aneiros-Fernandez J, de Lecea L, Culler MD, Hernandez-Cortes P, O'Valle F, Delgado M.

Circ Res. 2013 May 24;112(11):1444-55. doi: 10.1161/CIRCRESAHA.112.300695. Epub 2013 Apr 17.

PMID:
23595952
25.

Actions of Agonists and Antagonists of the ghrelin/GHS-R Pathway on GH Secretion, Appetite, and cFos Activity.

Hassouna R, Labarthe A, Zizzari P, Videau C, Culler M, Epelbaum J, Tolle V.

Front Endocrinol (Lausanne). 2013 Mar 18;4:25. doi: 10.3389/fendo.2013.00025. eCollection 2013.

26.

Effect of application route of the ghrelin analog BIM-28131 (RM-131) on body weight and body composition in a rat heart failure model.

Palus S, von Haehling S, Doehner W, Datta R, Zhang J, Dong JZ, Culler MD, Anker SD, Springer J.

Int J Cardiol. 2013 Oct 3;168(3):2369-74. doi: 10.1016/j.ijcard.2013.01.263. Epub 2013 Mar 7.

PMID:
23465234
27.

Chronic treatment with a melanocortin-4 receptor agonist causes weight loss, reduces insulin resistance, and improves cardiovascular function in diet-induced obese rhesus macaques.

Kievit P, Halem H, Marks DL, Dong JZ, Glavas MM, Sinnayah P, Pranger L, Cowley MA, Grove KL, Culler MD.

Diabetes. 2013 Feb;62(2):490-7. doi: 10.2337/db12-0598. Epub 2012 Oct 9.

28.

Adamantyl carboxamides and acetamides as potent human 11β-hydroxysteroid dehydrogenase type 1 inhibitors.

Su X, Halem HA, Thomas MP, Moutrille C, Culler MD, Vicker N, Potter BV.

Bioorg Med Chem. 2012 Nov 1;20(21):6394-402. doi: 10.1016/j.bmc.2012.08.056. Epub 2012 Sep 12.

29.

Effect of ghrelin and its analogues, BIM-28131 and BIM-28125, on the expression of myostatin in a rat heart failure model.

Lenk K, Palus S, Schur R, Datta R, Dong J, Culler MD, Anker S, Springer J, Schuler G, Adams V.

J Cachexia Sarcopenia Muscle. 2013 Mar;4(1):63-9. doi: 10.1007/s13539-012-0085-3. Epub 2012 Sep 18.

30.

Somatostatin analogs and chimeric somatostatin-dopamine molecules differentially regulate human growth hormone and prolactin gene expression and secretion in vitro.

Gruszka A, Culler MD, Melmed S.

Mol Cell Endocrinol. 2012 Oct 15;362(1-2):104-9. doi: 10.1016/j.mce.2012.05.020. Epub 2012 Jun 15.

PMID:
22705877
31.

Adropin deficiency is associated with increased adiposity and insulin resistance.

Ganesh Kumar K, Zhang J, Gao S, Rossi J, McGuinness OP, Halem HH, Culler MD, Mynatt RL, Butler AA.

Obesity (Silver Spring). 2012 Jul;20(7):1394-402. doi: 10.1038/oby.2012.31. Epub 2012 Feb 9.

32.

Beyond anchoring: the expanding role of the hendra virus fusion protein transmembrane domain in protein folding, stability, and function.

Smith EC, Culler MR, Hellman LM, Fried MG, Creamer TP, Dutch RE.

J Virol. 2012 Mar;86(6):3003-13. doi: 10.1128/JVI.05762-11. Epub 2012 Jan 11.

33.

Somatostatin dramatically stimulates growth hormone release from primate somatotrophs acting at low doses via somatostatin receptor 5 and cyclic AMP.

Córdoba-Chacón J, Gahete MD, Culler MD, Castaño JP, Kineman RD, Luque RM.

J Neuroendocrinol. 2012 Mar;24(3):453-63. doi: 10.1111/j.1365-2826.2011.02261.x.

PMID:
22129035
34.

Ghrelin and its analogues, BIM-28131 and BIM-28125, improve body weight and regulate the expression of MuRF-1 and MAFbx in a rat heart failure model.

Palus S, Schur R, Akashi YJ, Bockmeyer B, Datta R, Halem H, Dong J, Culler MD, Adams V, Anker SD, Springer J.

PLoS One. 2011;6(11):e26865. doi: 10.1371/journal.pone.0026865. Epub 2011 Nov 15.

35.

Somatostatin-dopamine chimeras: a novel approach to treatment of neuroendocrine tumors.

Culler MD.

Horm Metab Res. 2011 Nov;43(12):854-7. doi: 10.1055/s-0031-1287769. Epub 2011 Oct 11. Review.

PMID:
21989554
36.

Balance between somatostatin and D2 receptor expression drives TSH-secreting adenoma response to somatostatin analogues and dopastatins.

Gatto F, Barbieri F, Gatti M, Wurth R, Schulz S, Ravetti JL, Zona G, Culler MD, Saveanu A, Giusti M, Minuto F, Hofland LJ, Ferone D, Florio T.

Clin Endocrinol (Oxf). 2012 Mar;76(3):407-14. doi: 10.1111/j.1365-2265.2011.04200.x.

PMID:
21848909
37.

Ghrelin and obestatin modulate growth hormone-releasing hormone release and synaptic inputs onto growth hormone-releasing hormone neurons.

Feng DD, Yang SK, Loudes C, Simon A, Al-Sarraf T, Culler M, Alvear-Perez R, Llorens-Cortes C, Chen C, Epelbaum J, Gardette R.

Eur J Neurosci. 2011 Sep;34(5):732-44. doi: 10.1111/j.1460-9568.2011.07787.x. Epub 2011 Jul 21.

PMID:
21777303
38.

Adamantyl ethanone pyridyl derivatives: potent and selective inhibitors of human 11β-hydroxysteroid dehydrogenase type 1.

Su X, Pradaux-Caggiano F, Vicker N, Thomas MP, Halem H, Culler MD, Potter BV.

ChemMedChem. 2011 Sep 5;6(9):1616-29. doi: 10.1002/cmdc.201100182. Epub 2011 Jun 28.

39.

Discovery of adamantyl heterocyclic ketones as potent 11β-hydroxysteroid dehydrogenase type 1 inhibitors.

Su X, Vicker N, Thomas MP, Pradaux-Caggiano F, Halem H, Culler MD, Potter BV.

ChemMedChem. 2011 Aug 1;6(8):1439-51. doi: 10.1002/cmdc.201100144. Epub 2011 May 23.

40.

Ghrelin, peptide YY and their hypothalamic targets differentially regulate spontaneous physical activity.

Pfluger PT, Castañeda TR, Heppner KM, Strassburg S, Kruthaupt T, Chaudhary N, Halem H, Culler MD, Datta R, Burget L, Tschöp MH, Nogueiras R, Perez-Tilve D.

Physiol Behav. 2011 Nov 30;105(1):52-61. doi: 10.1016/j.physbeh.2011.04.025. Epub 2011 Apr 28.

PMID:
21554896
41.

Somatostatin analogs for the treatment of neuroendocrine tumors.

Culler MD, Oberg K, Arnold R, Krenning EP, Sevilla I, Díaz JA.

Cancer Metastasis Rev. 2011 Mar;30 Suppl 1:9-17. doi: 10.1007/s10555-011-9293-0. Review.

PMID:
21369878
42.

Somatostatin and dopamine receptor interaction in prostate and lung cancer cell lines.

Arvigo M, Gatto F, Ruscica M, Ameri P, Dozio E, Albertelli M, Culler MD, Motta M, Minuto F, Magni P, Ferone D.

J Endocrinol. 2010 Dec;207(3):309-17. doi: 10.1677/JOE-10-0342. Epub 2010 Sep 27.

PMID:
20876239
43.

Discovery of adamantyl ethanone derivatives as potent 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) inhibitors.

Su X, Pradaux-Caggiano F, Thomas MP, Szeto MW, Halem HA, Culler MD, Vicker N, Potter BV.

ChemMedChem. 2010 Jul 5;5(7):1026-44. doi: 10.1002/cmdc.201000081.

PMID:
20486152
44.

Taspoglutide, an analog of human glucagon-like Peptide-1 with enhanced stability and in vivo potency.

Sebokova E, Christ AD, Wang H, Sewing S, Dong JZ, Taylor J, Cawthorne MA, Culler MD.

Endocrinology. 2010 Jun;151(6):2474-82. doi: 10.1210/en.2009-1459. Epub 2010 Apr 9.

PMID:
20382695
45.

A potential inhibitory role for the new truncated variant of somatostatin receptor 5, sst5TMD4, in pituitary adenomas poorly responsive to somatostatin analogs.

Durán-Prado M, Saveanu A, Luque RM, Gahete MD, Gracia-Navarro F, Jaquet P, Dufour H, Malagón MM, Culler MD, Barlier A, Castaño JP.

J Clin Endocrinol Metab. 2010 May;95(5):2497-502. doi: 10.1210/jc.2009-2247. Epub 2010 Mar 16.

PMID:
20233783
46.

Differential Ligand-Mediated Pituitary Somatostatin Receptor Subtype Signaling: Implications for Corticotroph Tumor Therapy.

Ben-Shlomo A, Schmid H, Wawrowsky K, Pichurin O, Hubina E, Chesnokova V, Liu NA, Culler M, Melmed S.

Endocr Rev. 2009 Dec 1;30(7):933. doi: 10.1210/edrv.30.7.9983. No abstract available.

PMID:
28199544
47.

Regulation of prostate cancer cell proliferation by somatostatin receptor activation.

Ruscica M, Arvigo M, Gatto F, Dozio E, Feltrin D, Culler MD, Minuto F, Motta M, Ferone D, Magni P.

Mol Cell Endocrinol. 2010 Feb 5;315(1-2):254-62. doi: 10.1016/j.mce.2009.11.006. Epub 2009 Nov 20. Erratum in: Mol Cell Endocrinol. 2011 Jul 20;341(1-2):89.

PMID:
19932151
48.

Ghrelin in the regulation of body weight and metabolism.

Castañeda TR, Tong J, Datta R, Culler M, Tschöp MH.

Front Neuroendocrinol. 2010 Jan;31(1):44-60. doi: 10.1016/j.yfrne.2009.10.008. Epub 2009 Nov 5. Review.

PMID:
19896496
49.

Combined effects of ghrelin and higher food intake enhance skeletal muscle mitochondrial oxidative capacity and AKT phosphorylation in rats with chronic kidney disease.

Barazzoni R, Zhu X, Deboer M, Datta R, Culler MD, Zanetti M, Guarnieri G, Marks DL.

Kidney Int. 2010 Jan;77(1):23-8. doi: 10.1038/ki.2009.411.

50.

Differential ligand-mediated pituitary somatostatin receptor subtype signaling: implications for corticotroph tumor therapy.

Ben-Shlomo A, Schmid H, Wawrowsky K, Pichurin O, Hubina E, Chesnokova V, Liu NA, Culler M, Melmed S.

J Clin Endocrinol Metab. 2009 Nov;94(11):4342-50. doi: 10.1210/jc.2009-1311. Epub 2009 Oct 9.

PMID:
19820006

Supplemental Content

Loading ...
Support Center